EBV Infection Clinical Trial
Official title:
A Clinical Trial of PD-1 Monoclonal Antibody as First-line Induction Therapy for EBV-associated Hemophagocytic Syndrome (EBV-HLH) or Chronic Active EBV Infection (CAEBV)
EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown. This study is trying to evaluate the efficacy and safety of PD-1 monoclonal antibody as a first-line therapy for EBV-HLH and CAEBV.
Eligible patients who were diagnosed with EBV-HLH or CAEBV, age between 12 and 70 years, were enrolled in this study. All of them need to sign the informed consent first. PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age >=18 years, or age <18 years but weight >=40kg. While for patients age <18 years, the dose of PD-1 monoclonal antibody is 3mg/kg. Besides, optimal supportive care is necessary. Ruxolitinib and/or low-dose glucocorticoid can be used to reduce inflammation. Cerebrospinal fluid parameters are examined, and methotrexate 15mg combined with dexamethasone will be intrathecal injected without contraindications. Clinical and laboratory indicators are investigated weekly to evaluate the efficacy and toxicity. If patients achieve partial response/complete response within 14 days after PD-1 monoclonal antibody, the clinical observations are stopped. If not, the observation period is prolonged to 21 days. If disease progress at day 21, this study is terminated, and the patient should be transfer to other treatments as soon as quickly. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04084626 -
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
|
Phase 3 | |
| Completed |
NCT00711035 -
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04782674 -
Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases
|
||
| Active, not recruiting |
NCT03475212 -
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03159364 -
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04690036 -
PD-1 Antibody for Reactive EBV After BMT
|
Early Phase 1 | |
| Recruiting |
NCT03491605 -
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
|
||
| Recruiting |
NCT04189835 -
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
|
||
| Recruiting |
NCT04308278 -
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
|
Phase 4 | |
| Recruiting |
NCT05682703 -
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
|
||
| Completed |
NCT05604378 -
Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis
|
||
| Recruiting |
NCT04832607 -
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
|
Phase 3 | |
| Recruiting |
NCT06135922 -
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
|
Phase 1 | |
| No longer available |
NCT01945619 -
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
|
N/A |